Bavarian Nordic A/S logo

BAVA - Bavarian Nordic A/S Share Price

DKK296.2 2.7  0.9%

Last Trade - 16/04/21

Mid Cap
Market Cap £2.20bn
Enterprise Value £2.39bn
Revenue £215.8m
Position in Universe 220th / 1831
Unlock BAVA Revenue
Relative Strength (%)
1m +26.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.30%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1,021 1,007 1,370 500.6 662.5 1,852 2,158 2,671 +12.7%
+143.8 -33.3 +282.6
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BavarianNordic A/S revenues increased from DKR662.5M to DKR1.85B.Net income totaled DKR277.5M vs. loss of DKR346.8M.Revenues reflect United States segment increase of 86% toDKR1.14B, Other geographic markets segment increase fromDKR844K to DKR101.7M. Net Income reflects Other Researchand Development Costs decrease of 32% to DKR187.8M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BAVA
Graphical History


BAVA Revenue Unlock BAVA Revenue

Net Income

BAVA Net Income Unlock BAVA Revenue

Normalised EPS

BAVA Normalised EPS Unlock BAVA Revenue

PE Ratio Range

BAVA PE Ratio Range Unlock BAVA Revenue

Dividend Yield Range

BAVA Dividend Yield Range Unlock BAVA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BAVA EPS Forecasts Unlock BAVA Revenue
Profile Summary

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated July 1, 1992
Public Since November 2, 1998
No. of Shareholders: 69,640
No. of Employees: 475
Sector Healthcare
Industry Pharmaceuticals
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 63,684,407
Free Float (0.0%)
Eligible for
BAVA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BAVA
Upcoming Events for BAVA
Frequently Asked Questions for Bavarian Nordic A/S
What is the Bavarian Nordic A/S share price?

As of 16/04/21, shares in Bavarian Nordic A/S are trading at DKK296.2, giving the company a market capitalisation of £2.20bn. This share price information is delayed by 15 minutes.

How has the Bavarian Nordic A/S share price performed this year?

Shares in Bavarian Nordic A/S are currently trading at DKK296.2 and the price has moved by 0.114k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bavarian Nordic A/S price has moved by 65.6% over the past year.

What are the analyst and broker recommendations for Bavarian Nordic A/S?

Of the analysts with advisory recommendations for Bavarian Nordic A/S, there are there are currently 3 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bavarian Nordic A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bavarian Nordic A/S next release its financial results?

Bavarian Nordic A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bavarian Nordic A/S dividend yield?

Bavarian Nordic A/S does not currently pay a dividend.

Does Bavarian Nordic A/S pay a dividend?

Bavarian Nordic A/S does not currently pay a dividend.

When does Bavarian Nordic A/S next pay dividends?

Bavarian Nordic A/S does not currently pay a dividend.

How do I buy Bavarian Nordic A/S shares?

To buy shares in Bavarian Nordic A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bavarian Nordic A/S?

Shares in Bavarian Nordic A/S are currently trading at DKK296.2, giving the company a market capitalisation of £2.20bn.

Where are Bavarian Nordic A/S shares listed? Where are Bavarian Nordic A/S shares listed?

Here are the trading details for Bavarian Nordic A/S:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: BAVA
What kind of share is Bavarian Nordic A/S?

Based on an overall assessment of its quality, value and momentum, Bavarian Nordic A/S is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bavarian Nordic A/S share price forecast 2021?

Shares in Bavarian Nordic A/S are currently priced at DKK296.2. At that level they are trading at 6.05% discount to the analyst consensus target price of 0.00.

Analysts covering Bavarian Nordic A/S currently have a consensus Earnings Per Share (EPS) forecast of -2.393 for the next financial year.

How can I tell whether the Bavarian Nordic A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bavarian Nordic A/S. Over the past six months, the relative strength of its shares against the market has been 33.84%. At the current price of DKK296.2, shares in Bavarian Nordic A/S are trading at 40.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bavarian Nordic A/S PE Ratio?

The Bavarian Nordic A/S PE ratio based on its reported earnings over the past 12 months is 50.32. The shares are currently trading at DKK296.2.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bavarian Nordic A/S?

Bavarian Nordic A/S's management team is headed by:

Paul Chaplin - PRE
Gerard van Odijk - CHM
Anders Pedersen - VCH
Erik Hansen - IND
Peter Kurstein-Jensen - IND
Frank Verwiel - IND
Henrik Birk - COO
Elizabeth McKee Anderson - IND
Henrik Juuel - CFO
Anne Eberhard - IND
Jean-Christophe May - EVP
Laurence De Moerlooze - EVP
Anu Kerns - EVP
Who are the major shareholders of Bavarian Nordic A/S?

Here are the top five shareholders of Bavarian Nordic A/S based on the size of their shareholding:

ATP Pension Fund
Percentage owned: 10.11% (6.44m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 4.59% (2.92m shares)
Invesco Global Opportunities Fund Mutual Fund
Percentage owned: 4.52% (2.88m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.83% (1.80m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 2.83% (1.80m shares)
Similar to BAVA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.